Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab

Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab

Jahnavi Gollamudi,1,* Jenny G Parvani,2,* William P Schiemann,3 Shaveta Vinayak3,4 1Department of Internal Medicine, 2Department of Biomedical Engineering, 3Case Comprehensive Cancer Center, Case Western Reserve University, 4Department of Hematology and Oncology, University Hospitals Case Medical Ce...

Full description

Bibliographic Details
Main Authors: Gollamudi J, Parvani JG, Schiemann WP, Vinayak S
Format: Article
Language:English
Published: Dove Medical Press 2016-02-01
Series:Cancer Management and Research
Subjects:
breast cancer
HER2
monoclonal antibody
neoadjuvant
pertuzumab
receptor tyrosine kinase
signal transduction
trastuzumab
Online Access:https://www.dovepress.com/neoadjuvant-therapy-for-early-stage-breast-cancer-the-clinical-utility-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/neoadjuvant-therapy-for-early-stage-breast-cancer-the-clinical-utility-peer-reviewed-article-CMAR

Similar Items